Factores que inﬂuyen en las diferencias entre la evaluación global de la actividad de la enfermedad por el paciente y por el médico en pacientes con artritis psoriásica

J. Gallino Yanzi; O.L. Cerda; M. Landi; C.A. Zaffarana; E.E. Schneeberger; G. Citera

doi:10.47196/rar.v27i3.581

J. Gallino Yanzi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
O.L. Cerda Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
M. Landi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
C.A. Zaffarana Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
E.E. Schneeberger Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
G. Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v27i3.581

Palabras clave: artritis psoriásica, actividad de la enfermedad por el médico, actividad de la enfermedad por el paciente

Resumen

Objetivo: Evaluar los factores que inﬂuyen en la evaluación global de la actividad por el paciente (EGEp) y el médico (EGEm) en pacientes con Artritis Psoriásica (APs).

Citas

I. Arturi A. Diagnóstico en Reumatología y Enfermedades Autoinmunes Sistémicas. Edición Abbvie. Capítulo 8. Pág. 197-202. 2014.

II. Soriano E, Rosa J, Velozo E, Schpilberg M, Imamura P, Díaz J, et al. Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology 2011;50(4):729-34.

III. Maldonado Cocco J, Citera G. Reumatología. Segunda Edición, Ediciones Azzurras. Capítulo 33. Pág 462-70. 2012.

IV. Eder L, Thavaneswaran A, Chandran V, Cook R, Galdman D. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res 2015;67(2):264-72.

V. Gladman D, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34(5):1167-70.

VI. Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK, et al. Construct validity of the modified numeric rating scale of patient global assessment in psoriatic arthritis. J Rheumatol 2012;39(4):844-8.

VII. Dandorfer SW, Rech J, Manger B, Schett G, Englbrecht M. Differences in the patient’s and the physician´s perspective of disease in psoriatic arthritis. Semin Arthritis Rheum 2012;42(1):32-41.

VIII. Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004;31(7):1293-6.

IX. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res 2010;62(6):857–64

X. B erkanovic E, Hurwicz ML, Lachenbruch PA. Concordant and discrepant views of patients’ physical functioning. Arthritis Care Res 1995;8(2):94–101.

XI. T aylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73.

XII. W olfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2):160-72.

XIII. Gladman D, Mease P, Healy P, Helliwell P, Fitzgerald O, Cauli A, et al. Outcome measures in PsA. J Rheumatol 2007; 34(5): 1159-66.

XIV. M arks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progression in psoriasis. Arch Dermatol 1989;125 (2):235-40.

XV. Doward LC, Spoorenberg A, Cook SA, Whaley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62(1):20-6.

XVI. M cKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63(2):162-9.

XVII. Citera G, Arriola MS, Maldonado Cocco JA, Rosemffet MG, Sánchez MM, Goñi MA, et al. Validation and crosscultural adaptation of an Argentine Spanish version of the health assessment questionnaire disability index. J Clin Rheumatol 2004;10(3):110-5.

XVIII. C alin A, Garrett SL, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to functional ability in ankylosing spondylitis. J Rheumatol 1994;21(12):2281-5.

XIX. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21(12):2286-91.

XX. F elson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36(6):729-40.

XXI. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70(2):272-7.

XXII. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69(8):1441-7.

XXIII. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38 (5):898-903.

XXIV. Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?. J Rheumatol 2015; 42 (12): 2332-8.